11月19日，普洛药业(000739.SZ)发布公告称，公司拟使用自有资金及金融机构回购贷款通过深圳 证券交易所交易系统以集中竞价交易方式回购公司股份，回购股份价格不超过人民币23元/股，回购资 金总额为不低于1.8亿元（含）且不超过3.6亿元（含）。 预计可回购股份数量为783万股—1565万股，约占公司总股本的0.68%—1.35%。回购期限为自董事 会审议通过回购股份方案之日起12个月内。 若公司在股份回购完成后36个月内未能实施前述用途，未使用部分将依法履行相关程序后予以注 销。 ...

Summary of Key Points from Conference Call Records Industry Overview - The pharmaceutical industry is generally optimistic, with signs of a rebound in the innovative drug sector. Large-cap companies have seen declines of over 30%, while small-cap companies have dropped more than 50%, indicating a potential opportunity for stock alpha in the coming year [1][2][4]. Key Companies to Watch - **Innovative Drug Sector**: Focus on companies like Innovent Biologics and China National Pharmaceutical Group, as well as smaller firms like Genscript Biotech and Luyin Pharmaceutical [1][4]. - **Medical Devices**: Companies such as Mindray and Spring Medical are highlighted for their recovery and growth potential in high-value consumables and medical equipment [5][6]. - **Traditional Chinese Medicine**: Increased institutional interest, with companies like Yiling Pharmaceutical and China Resources Sanjiu expected to benefit from a recovery in the sector [1][7][9]. - **CRO and API Sectors**: Kanglong Chemical and ProPharma are noted for their growth potential, particularly in clinical research and API business recovery [1][10][11]. Market Trends and Opportunities - **High-Value Consumables**: The pressure from centralized procurement is easing, leading to a reassessment of value driven by innovation [5][6]. - **Blood Products**: The sector is in an adjustment phase but shows signs of reversal, with supply tightening expected in 2026 [3][12][15][16]. - **Oral Peptide Drugs**: New oral formulations like Merck's MK0,616 and Johnson & Johnson's GNG2,113 show promise in treating chronic diseases, with potential to change administration methods and improve patient compliance [3][17][20][27]. Financial Performance and Projections - **Kanglong Chemical**: Expected adjusted net profit of 2.12 billion yuan by 2026, with a price-to-earnings ratio of 25 times [11]. - **ProPharma**: Anticipated to see a compound annual growth rate exceeding 20% by 2027, with a current P/E ratio of about 14 times [11]. - **Tianyu Co.**: Projected profit of 300 million yuan for the year, with a growth rate of over 30% expected [14]. Challenges and Considerations - **Regulatory and Market Dynamics**: The medical device sector faces pressures from policy changes and international competition, necessitating innovation and adaptation [5][6]. - **Blood Product Supply**: The industry is experiencing a supply-demand imbalance, with potential for improvement as new products are introduced [12][15][16]. - **Oral Peptide Development**: Challenges in molecular modification and large-scale production remain significant hurdles for the commercialization of new oral peptide drugs [27]. Conclusion - The pharmaceutical and medical device industries are poised for growth, with several companies showing strong potential for recovery and innovation. Investors are encouraged to focus on key players within these sectors, particularly those involved in innovative drug development and high-value medical devices, as they navigate the evolving market landscape [1][4][5][11][14].

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 000566 | 海南海药 | 8.38 | 5.81% | 399.60万 | | 34.45 Z | | 600200 | *ST苏吴 | 1.12 | 4.67% | 67.18万 | | 7354.24万 | | 000739 | 普洛药业 | 15.84 | 1.41% | 17.06万 | | 2.71亿 | | 688117 | 圣诺生物 | 38.09 | 1.17% | - 3.35万 | | 1.25亿 | | 688506 | 百利天恒 | 374.66 | -0.11% | 8452.29 | | 3.17亿 | | 688578 | 艾力斯 | 95.49 | -0.12% | 3.69万 | | 3.54亿 | | 003020 | 立方制药 | 27.67 | -0.65% | 4.31万 | | 1.19亿 | | 002653 | 海温泉 | 56.19 | -0.86% | 3.98万 | | 2 ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-70 普洛药业股份有限公司 关于 2025 年第二次回购股份报告书 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1.普洛药业股份有限公司（以下简称"公司"）于 2025 年 11 月 18 日召开 第九届董事会第十七次会议，经全体董事审议，一致通过了《关于 2025 年第二 次回购公司股份方案的议案》。根据《公司章程》的相关规定，本次回购股份方 案属于董事会审批权限范围，无需提交股东大会审议。 2.公司拟使用自有资金及金融机构回购贷款以集中竞价交易方式回购公司 股份，本次回购资金总额为人民币 18,000 万元—36,000 万元，本次回购股份价 格不超过人民币 23 元/股，未超过公司董事会通过回购股份决议前三十个交易日 公司股票交易均价的 150%。具体回购数量以回购期限届满或者回购股份实施完 毕时实际回购的股份数量为准。回购期限为自董事会审议通过回购股份方案之日 起 12 个月内。 3.公司已在中国证券登记结算公司深圳分公司开立了回购股份专用证券账 户。 4.截至本公告披 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 普洛药业股份有限公司（以下简称"公司"）于2025年11月18日召开了第九 届董事会第十七次会议，审议通过了《关于2025年第二次回购公司股份方案的议 案 》 ， 并 于 2025 年 11 月 20 日 在 《 证 券 时 报 》 及 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露了《关于2025年第二次回购公司股份方案的 公告》（公告编号：2025-67）。 根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监管指引 第9号——回购股份》等相关规定，现将公司董事会公告回购股份决议的前一个 交易日（即2025年11月19日）登记在册的前十名股东和前十名无限售条件股东名 称、持股数量及占总股本比例情况公告如下： | 序号 | 持股人名称 | 持股数量（股） | 占总股本比例（%） | | --- | --- | --- | --- | | 1 | 横店集团控股有限公司 | 330,941,729 | 28.57 | | 2 | 浙江横店进出口有限公司 | 156,552,90 ...

Industry Events - The 2025 China 5G + Industrial Internet Conference will be held from November 21 to 23 in Wuhan, focusing on the integration of 5G, AI, big data, and industrial internet technologies [2] - The China Rare Earth Society's 2025 Academic Annual Meeting will take place on November 21 in Xiamen, discussing advancements in rare earth research and applications [2] - Huawei will release breakthrough AI technology on November 21, aiming to increase the utilization rate of computing resources from the industry average of 30%-40% to 70% [2] - Foxconn will showcase new products in collaboration with Nvidia during the Hon Hai Technology Day on November 21 [2] Company News - Walmart announced its transition from the New York Stock Exchange to Nasdaq, with trading expected to begin on December 9 [12] - Tuojing Technology's major shareholder plans to reduce its stake by up to 843.49 million shares, representing 3% of the total share capital, from December 12, 2025, to March 11, 2026 [12] - Qianyuan High-Tech received a takeover offer from China Seed Group for 20% of its total shares at a price of 11.85 yuan per share, totaling an estimated 2.245 billion yuan [12] - Fosun Pharma's subsidiary has received breakthrough therapy designation for its independently developed drug for gastric cancer, marking a significant milestone in treatment options [12] - *ST Weihai signed a construction contract worth 313 million yuan, which is expected to positively impact the company's future performance [12][13] Market Trends - Multiple new energy-themed ETFs have attracted significant capital inflows, with the Huatai-PineBridge CSI Battery Theme ETF seeing a net subscription of 1.696 billion yuan since the fourth quarter began [16] - Institutional investors are focusing on rebalancing their portfolios as the year-end approaches, with an emphasis on sectors like cyclical stocks and consumer goods [8][7] Supply and Demand Insights - Tungsten prices continue to rise due to favorable supply and demand dynamics, with prices for various tungsten products increasing by approximately 6% compared to the first half of November [10] - The overall price of tungsten products has surged over 120% this year, driven by increased demand from industries such as photovoltaics and automotive [10]

Core Viewpoint - Pro Pharmaceutical Co., Ltd. announced that its subsidiary, Zhejiang Pro Kangyu Pharmaceutical Co., Ltd., has received a drug registration certificate for Cefdinir capsules from the National Medical Products Administration [2] Group 1 - The announcement was made on the evening of November 20 [2] - The drug registration certificate is a significant regulatory milestone for the company [2] - Cefdinir is an antibiotic used to treat various bacterial infections, indicating potential market opportunities for the company [2]

Group 1 - EVE Energy signed a procurement framework agreement with its affiliate, Smoore International, for continuous procurement of battery cells starting from January 1, 2026 [1] - Zhaoyi Information plans to issue H-shares and list on the Hong Kong Stock Exchange [1] - Fuke Environmental announced a change in its stock abbreviation to "Fuke Technology" effective November 26 [1] Group 2 - Dajia Weikang's shareholder and director terminated a share reduction plan ahead of schedule, having reduced 1% of total shares [2] - Aohong Electronics received approval from the China Securities Regulatory Commission for the issuance of convertible bonds [2] - Yingfeng Environment's controlling shareholder plans to issue exchangeable bonds not exceeding 1 billion yuan [2] Group 3 - Longshen Rongfa's subsidiary obtained a renewed drug production license covering various pharmaceutical products [4] - Xinhua News' subsidiary invested 15 million yuan in a fund with a total commitment of 221 million yuan [5] - Guang'an Aizhong appointed two new deputy general managers [6] Group 4 - Fosun Pharma's subsidiary's drug for gastric cancer treatment was included in the breakthrough therapy program by the National Medical Products Administration [7] - Nanjiao Foods reported a significant decline in October net profit due to rising raw material costs [8] - Nanfeng Co. won two nuclear power project bids totaling 928.7 million yuan [10] Group 5 - Puluo Pharmaceutical received a drug registration certificate for its Cefdinir capsules [11] - Liming Co.'s subsidiary received environmental approval for a new pesticide raw material project [12] - Longhua New Materials' expansion project for polyether polyols has commenced trial production [13] Group 6 - Pumen Technology's products received IVDR CE certification from TÜV Rheinland [15] - China Chemical reported new contracts worth 312.67 billion yuan from January to October [18] - China Nuclear Construction achieved new contracts totaling 123.84 billion yuan as of October [19] Group 7 - Changshu Bank's executives plan to purchase at least 550,000 shares of the bank [20] - Shandong Steel's subsidiary is applying for bankruptcy liquidation to focus on core business [21] - Huakang Clean is expected to win a bid for a purification system project worth 176 million yuan [23] Group 8 - Huawu Co. plans to internally transfer subsidiary equity [24] - Tianen Kang's subsidiary received clinical trial acceptance for a new drug [26] - Tianyi Medical's subsidiary obtained a medical device registration certificate for a blood dialysis product [27] Group 9 - Xuelang Environment is facing a pre-restructuring application from creditors [27] - Chitianhua's subsidiary resumed production after passing safety inspections [28] - Huaping Co.'s director plans to reduce 0.03% of company shares [30] Group 10 - Xizhuang Co. plans to establish a wholly-owned subsidiary in Singapore [31] - Ruisheng Intelligent's subsidiary won a 60.23 million yuan ICT project bid [32] - Junyi Digital plans to invest 120 million yuan in Guanghong Precision [33] Group 11 - Fuguang Co.'s controlling shareholder plans to increase holdings between 80 million to 150 million yuan [34] - Ganyue Express reported a 13.68% increase in logistics revenue in October [39] - Jiangsu Sop terminated its 2025 private placement plan [41] Group 12 - Langke Intelligent's shareholders plan to reduce a total of 1.68% of company shares [42] - Yuantong Express reported an 8.97% increase in express product revenue in October [45] - Jinbei Automotive plans to invest 158 million yuan to acquire 52% of Zhongtuo Technology [46]

Group 1 - Prolo Pharmaceutical Co., Ltd. announced that its subsidiary, Zhejiang Prolo Kangyu Pharmaceutical Co., Ltd., received a drug registration certificate for Cefdinir capsules from the National Medical Products Administration [1] - For the first half of 2025, Prolo Pharmaceutical's revenue composition is 99.6% from the pharmaceutical industry and 0.4% from other businesses [1] - As of the report date, Prolo Pharmaceutical has a market capitalization of 18.1 billion yuan [1]

Core Viewpoint - Pro Pharmaceutical Co., Ltd. has received a drug registration certificate for Cefdinir capsules from the National Medical Products Administration, indicating a significant development in its product portfolio [1] Group 1: Company Developments - The company’s subsidiary, Zhejiang Pro Pharmaceutical Co., Ltd., is the entity that received the drug registration certificate for Cefdinir capsules [1] - Cefdinir capsules are indicated for infections caused by various bacteria, including Staphylococcus, Streptococcus, and Escherichia coli, among others [1] Group 2: Product Indications - The indications for Cefdinir capsules include infections such as pharyngitis, tonsillitis, acute bronchitis, pneumonia, otitis media, sinusitis, pyelonephritis, cystitis, and gonococcal urethritis [1] - Additional indications cover conditions like pelvic inflammatory disease, intrauterine infections, and various skin and soft tissue infections [1]